
|Videos|November 14, 2013
Compounding Pharmacy Regulation and Office Use
David G. Miller, RPh, discusses concerns regarding the regulatory status of compounding medications for office use by physicians or dentists.
Advertisement
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses his concern that in reaffirming section 503A of the Federal Food, Drug, and Cosmetic Act, H.R. 3204 (the Drug Quality and Security Act) would leave pharmacists who compound medications for office use by physicians and dentists in an ambiguous regulatory position. This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
4
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
5


































































































